53 results about "Human lung" patented technology

A drug testing platform for simulating a lung environment includes a microfluidic chip and a stretching device. The microfluidic chip defines a microfluidic channel structure. The microfluidic channel structure includes a test unit, a cell shunt unit and a drug shunt unit. The stretching device is configured to stretch and contract the test unit in a manner of a reciprocal motion, thereby making degree of deformation of a plurality of test area of the test unit to be same during the reciprocal motion. The drug testing platform for simulating the lung environment according to the present disclosure may configure an environment that simulates a breathing motion of a human lung, and obtain multiple results within a single test.

The present invention relates to a polysaccharide with cytotoxic activity against human colon, human lung, human melanoma and murine leukaemia tumour cells, as well as antioxidant and healing activity. The invention also relates to a method for producing the polysaccharide, its uses and applications, particularly via drugs for treating cancer and / or antioxidant and healing compositions. The polysaccharide of the present invention can be produced from biomass, particularly from fungi, and preferably from the fungus Bovistella utriformis.

The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.

The invention discloses a construction method and application of a human lung 3D cell microsphere and a human pulmonary fibrosis 3D organoid. The construction of the human lung 3D cell microspheres comprises the following steps: respectively digesting human primary fibrosis cells and human II-type alveolar epithelial cells which are subjected to adherent culture into single cells; mixing digested human primary fibrotic cells, human II-type alveolar epithelial cells and THP-1 macrophages subjected to suspension culture according to a cell number ratio of 1: 1: 1, so as to obtain a cell precipitate; and preparing the cell precipitate into cell matrigel microspheres by using a T-type microfluidic technology, and culturing to obtain the human lung 3D cell microspheres. And further inducing the human lung 3D cell microspheres by using a human lung organoid culture medium containing 50ng / mL of TGF-beta for 24-48 hours to obtain the human pulmonary fibrosis 3D organoid. According to the invention, 3D cell microspheres with human normal lung cell characteristics and protein expression can be formed within 3 days, and pulmonary fibrosis 3D organs can be obtained after short-time induction.

The invention provides a lung-kidney interaction simulation system based on an organ chip, and the system comprises a lung chip module which is used for simulating a qi-blood barrier structure of a lung, and the lung chip module is inoculated with human alveolar epithelial cells and human lung microvascular endothelial cells; the kidney chip module is used for simulating a capillary lumen of a kidney tubule and a kidney tubule lumen structure, and human kidney tubule epithelial cells and human umbilical vein endothelial cells are inoculated on the kidney chip module; the connecting channel is used for communicating the lung chip module with the kidney chip module and allowing the culture medium to flow between the lung chip module and the kidney chip module; and wherein a klebsiella pneumoniae liquid for causing lung injury is applied to the upper layer of the lung chip module. The invention provides a novel simulation system for the research of lung-kidney interaction, and solves the limitation of animal experiments.

The present invention relates to a treatment of cancer. Here, the inventors discovered that flavin-containing monooxygenase 4 (FM04) expression was increased in lung tumor samples compared with lung healthy tissue. They found that this phenotype was a common feature in lung adenocarcinoma promoted also by translocation of EML4 / ALK as well as by oncogenic KRAS or EGFR using dedicated mouse models. Moreover, FMO4 was strongly increased in human lung tumors compared with healthy lung tissue, and FMO4 expression was inversely correlated with overall survival in patients with lung adenocarcinoma. Importantly, FMO4 protected lung cancer cells against reactive oxidative species-induced apoptosis. Finally, FMO4 loss of function decreased oncogenic KRAS-induced human bronchoalveolar cells transformation in vitro and in vivo. Thus, the present invention relates to an FMO inhibitor for use in the treatment of cancer in a subject in need thereof.

The invention discloses an integrated valvular catheter and a preparation method thereof, relates to the technical field of medical instruments, and aims to solve the problems that in a traditional valvular catheter operation, suturing is tedious, tearing and thrombus risks exist, and adaptability is insufficient. The integrated valve-containing pipeline is composed of a valve leaflet and a pipeline body which are integrated through the sintering effect, sewing is not needed, and the reflux and thrombus risks caused by sewing gaps are effectively avoided; a metal memory alloy support is embedded in the wall of the pipeline, so that support can be provided for the valved pipeline to stabilize haemodynamics and prevent the pipeline from collapsing, endovascular intervention delivery can be achieved, and the device is adaptive to a surgical opening mode or an endovascular implantation mode and is used for replacing the valved pipeline at parts such as pulmonary artery and lower limb deep vein of a human body and recovering the function of the damaged valve.

An endobronchial tool training device may include a simulated human lung main airway network, and at least one training cartridge removably coupled to the simulated human lung main airway network. The training cartridge may include a body of simulated lung tissue having at least one simulated abnormality, and a simulated human lung branch airway network. An endobronchial tool is steerable through the simulated human lung main airway network and into the simulated human lung branch airway network to a position adjacent at least one simulated abnormality.

The invention relates to a high-invasiveness human lung adenocarcinoma brain metastasis cell line and application thereof, the cell line is named as a human lung adenocarcinoma brain metastasis cell line A549-F3, the cell line is preserved in China Center for Type Culture Collection on March 31, 2025, and the preservation number is CCTCC NO: C2025107. The A549-F3 cell line with high invasiveness and stable brain metastasis characteristics is successfully constructed through an in-vivo circulation screening method, the defects of an existing cell line in lung adenocarcinoma brain metastasis research are overcome, and a more suitable cell model is provided for deep exploration of related mechanisms.

The application discloses a butyl tin-cycloiridium phenanthroline complex with an aggregation-induced emission (AIE) property, a preparation method of the complex and anticancer application of the complex. The structural formula of the complex is shown as formula (I), and R is one of hydrogen, a phenyl group, a p-tolyl group, a p-bromophenyl group, a p-fluorophenyl group, a biphenyl group, a triphenylamine group, a carbazole group, a tetraphenyl ethene group and a triphenylbenzene group. The growth inhibition rates of the target compound on human alveolar basal epithelial carcinoma cells (A549) and cisplatin-resistant cells (A549 / DDP), cervical cancer cells (Hela) and human lung normal epithelial cells (BEAS-2B) are tested, and it is found through comparison that the target compound shows potential anticancer activity. In addition, the target compound shows unique AIE emission characteristics. The target compound mainly targets the lysosomes of A549 cells, and influences the mitochondria to cause the decline of the mitochondrial membrane potential, thereby showing anticancer activity.

This invention discloses a method for constructing lung organoids with spontaneous vascularization and branching morphology. By optimizing the culture protocol and progressively inducing directional mesoderm, vascularized foregut endoderm, vascularized lung bud organoids, and vascularized lung organoids, lung organoids with both vascularization and branching morphology are successfully cultured, thus more realistically simulating the structural characteristics of the human lung. This invention has significant advantages: First, it can effectively induce the formation of vascularization and branching structures in lung organoids, overcoming the shortcomings of traditional lung organoids that lack vascularization and branching structures; second, by adjusting the culture method in the early stages, the uniformity of the lung organoids is significantly improved, enhancing the reliability and reproducibility of experimental results. This invention provides a more precise and efficient experimental platform for preclinical studies such as lung disease research, drug screening, and toxicology testing, and has significant application value.

The invention belongs to the technical field of cell biology, and particularly relates to a triple co-culture cell model for respiratory function research as well as a construction method and application of the triple co-culture cell model. Based on BEAS-2B, THP-1 and MRC-5 cells, a triple co-culture cell model is constructed by adopting a Transwell three-dimensional construction mode, and a complex cell interaction environment after human respiratory tract tissues are exposed to harmful factors such as heavy metals and the like can be simulated. The constructed model is closer to a real physiological anatomical structure in structure, and the multicellular synergistic toxic reaction caused by heavy metal exposure is more comprehensively reproduced in a functional level; an integrated in-vitro model which is closer to human lung tissue in structure, covers multi-stage reaction in function, is standard and stable in operation and has multi-dimensional analysis capability in mechanism is realized for the first time, scientificity, sensitivity and practical applicability of research on respiratory system toxicity caused by heavy metal are remarkably improved, and the method has relatively high technical advancement and industrial transformation potential.

The invention represents new hybrid compounds of two natural products sclareol and doxorubicin in the form of their conjugates. These compounds are in the form of conjugates, where doxorubicin and sclareol are covalently linked by a linker in a 1:1 molar ratio. The hybrids have shown to possess anticancer properties and are effective in treating resistant cancer cells that have P-glycoprotein membrane transporter, responsible for resistance to doxorubicin. The hybrids have been tested on different types of cell lines, including human glioblastoma, non-small cell lung carcinoma, and colorectal carcinoma. Also, a method for their preparation and their use in medical products or pharmaceutical preparations has been determined. The results of the study include the cytotoxic activity of single, combined, and conjugated compounds in pairs of sensitive and resistant cancer cells, with and without P-glycoprotein expression. The selectivity towards cancer cells was determined by comparing with commercially available normal human lung fibroblast cells. The study also investigated the nanoparticle nature of hybrid compounds, their intracellular localization and toxicity in vivo.

The application discloses a WUPyV infection model and a construction method and application thereof, and the construction method comprises the following steps: (1) culturing proximal differentiated lung organoids; (2) removing collagen from the lung organoids to prepare lung organoid ball suspension, mixing the lung organoid ball suspension with a WUPyV sample, and co-incubating and infecting; and (3) re-embedding the lung organoids in basement glue after infection, and continuing to culture in a basic culture medium to obtain the WUPyV infection model. The WUPyV infection model is constructed by using three-dimensional human lung organoids, WUPyV can be separated and cultured, the infection process of WUPyV in human lung organs can be better simulated and characterized, and a new infection model is provided for WUPyV infection pathogenesis and body innate immune response mechanism and interaction between viruses and host cells.

This invention discloses a biomimetic system simulating lung tissue, its manufacturing method, and a method for controlling microfluidics using this biomimetic system. The biomimetic system comprises lung epithelial cells, lung fibroblasts, and human umbilical vein endothelial cells isolated from human lungs, and is perfused with microfluidics. Gas and a fluid including culture medium can be perfused into the internal chambers of the system, simulating similar respiratory movements. Even after more than a week following perfusion, the three types of cells within the system can survive. Furthermore, pH and pO2 within the chambers can be monitored using pH and gas partial pressure sensors within the system, allowing the three types of cells to be exposed to the external environment or drugs under conditions similar to those of a living lung. This enables research in a wide range of fields, including modeling lung diseases caused by harmful substances and testing the efficacy of therapeutic drugs. It is also applicable to in vitro disease modeling and customized drug formulation.

The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.

The disclosure is generally directed to a composition, method and system of respiratory organoids that sustain propagation of respiratory pathogens. Also provided is a method of modeling a biological process in a human lung. Also provided is a method of screening for compounds that affect respiratory pathogens in a respiratory organoid model.

The present invention relates to the application of METTL3 in the preparation of drugs for preventing and treating radiation-induced lung injury. The present invention discovers that METTL3 knockdown has a preventive and therapeutic effect on radiation injury of human lung cells and lung tissues in animal models, can inhibit the epithelial-mesenchymal transition process during the occurrence and development of radiation-induced lung injury, and enhance the antioxidant and post-radiation cell proliferation abilities of lung cells. Therefore, the preventive and therapeutic drugs of the present invention are designed with METTL3 as the target gene, and have important significance and application value in dealing with nuclear and radiation accidents, nuclear emergencies, and reducing the lung radiation injury of tumor radiotherapy patients, etc.

The invention discloses a biomarker for diagnosing pulmonary fibrosis and application thereof, and belongs to the technical field of clinical medicine. The pulmonary fibrosis biomarker lncRNA DLEU2 provided by the invention can effectively assist in diagnosing patients with pulmonary fibrosis, and activation of human lung fibroblasts can be effectively inhibited in the human lung fibroblasts through a knock-down agent sh-DLEU2.

The application discloses a human lung large cell neuroendocrine carcinoma cell line and application, the cell line is preserved in China typical culture preservation center, the preservation time is August 22, 2024, the preservation number is CCTCC NO:C2024278, and the culture name is human lung large cell neuroendocrine carcinoma cell strain ZX2024C.The cell line can be stably passed, can keep the biological characteristics of human lung large cell neuroendocrine carcinoma cell, no human cell cross contamination is found, and has abnormal chromosome karyotype, can form tumor in the body of nude mouse, can be applied to the preparation of lung large cell neuroendocrine carcinoma diagnostic product, screening lung large cell neuroendocrine carcinoma drug, researching lung large cell neuroendocrine carcinoma cell proliferation mechanism, constructing mammalian lung large cell neuroendocrine carcinoma animal model.

The application discloses a culture medium for constructing a liver cancer lung metastasis microtumor model and application thereof. The application relates to the technical field of biology, and provides a culture medium for constructing a liver cancer lung metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant proteins EGF, HGF, IL-2, IL-15, R-spondin1, CXCL12, recombinant human lung surfactant proteins SP-A, SP-D, forskolin, A83-01, N-acetyl-L-cysteine, nicotinamide, N2 additives, B27 and a basic culture medium. The culture success rate of the liver cancer lung metastasis microtumor model is effectively improved.

The invention discloses a severe respiration restorer, and particularly relates to the technical field of respiration restorers, the severe respiration restorer comprises two shells, the two shells are oppositely arranged, a respiration recovery assembly is arranged between the two shells, the respiration recovery assembly comprises a connecting plate arranged between the two shells, two butt joints are arranged on one side of the connecting plate, and the two butt joints are oppositely arranged on the other side of the connecting plate. And a mixing bin is arranged on the other side of the connecting plate. Through a linkage structure of the driving motor, the eccentric block, the spring and the plug, the top plate can be alternately pushed to compress the first spring, the plug is driven to block the conveying valve, or the first spring is reset to enable the plug to be separated from the conveying valve, and the process can accurately simulate the physiological rhythm of airflow conduction during inspiration of the lung of the human body and temporary airflow closing during expiration. Compared with an existing device only capable of supplying air continuously, the device effectively avoids damage of continuous air pressure to the lung, meanwhile, it is guaranteed that carbon dioxide is smoothly discharged during expiration, and the core requirements of critical patients for respiratory support physiology and low damage are met.

1. The name of the design product: spirometer. 2. The use of the design product: the design product is used for human lung capacity breathing test. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

Disclosed are a biomimic system simulating lung tissue, a method for manufacturing same, and a microfluidic control method using same, wherein the biomimic system comprises lung epithelial cells and lung fibroblasts, which are isolated from human lungs, and commercially available vascular endothelial cells, and wherein a microfluid flows through the biomimic system. Each chamber inside the corresponding system can allow a fluid, which contains gas and a medium, to flow therethrough and simulate respiration-like movement, wherein all of the three types of cells can survive inside the system even when one week or more have elapsed after through-flow of the fluid. In addition, the pH and pO2 in the chamber can be monitored by using a pH sensor and a gas partial pressure sensor inside the system, and thus the three types of cells inside the system can be exposed to external environments, drugs, and the like under the same conditions as in the lungs in vivo. Therefore, a wide range of studies including modeling of lung diseases by harmful substances and testing of therapeutic drug efficacy can be conducted, and further, the utilization to in vitro disease modeling, customized medicine prescriptions, and the like can also be made.

The invention discloses a magnetic tile internal crack defect detection device capable of simulating generation of damp and hot air in human lung. The damp and hot gas generation mechanism is located on the side of the rack, one end of the damp and hot gas generation mechanism extends into the environment detection mechanism and is used for spraying damp and hot gas to the surfaces of the magnetic shoes in the environment detection mechanism, and the conveying belt and the environment detection mechanism are both installed on the upper surface of the rack; the feeding end of the conveying belt is provided with a limiter used for limiting the placement position of the magnetic shoe, and the environment detection mechanism is installed above the conveying belt, connected with the upper surface of the rack, covers a section of conveying area of the conveying belt and is used for observing water mist distribution and detecting the inner crack defect of the magnetic shoe. The device adopts a novel nondestructive testing method to ensure that water mist uniformly covers the surface of the magnetic tile to detect the defects such as cracks and air holes in the magnetic tile through differential pressure-temperature difference synergistic adsorption, so that the manual detection efficiency is improved, and the device is suitable for industrial quality inspection of magnetic materials.

The utility model provides a protection effect test detection system for respiratory protection articles. The protection effect test detection system comprises a sealed cabin; the material generator comprises a dust generator, an organic solvent generator and a concentration controller; the temperature control device comprises a heater, a refrigerating system and a temperature sensor; the humidity control device comprises a humidifier and a dehumidifier; the human breathing simulating device comprises human lung simulating equipment, breathing simulating temperature control equipment and breathing simulating humidity control equipment; the ventilation and purification device comprises an air draft pipeline, an air exhaust pipeline and air purification equipment; air purification equipment is arranged on the air exhaust pipeline; and the detection device comprises two particulate matter counters. The protection effect test detection system for the respiratory protection articles is used for simulating the protection effect and influence factors of the respiratory protection articles in a working environment in a sealed cabin.

The present disclosure provides a single mouse exhaled breath collection device and proof- of-concept analyses utlizing an ultra- sensitive and customizable EV purification assay, EV- CATCHER® (Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release) assay. Preliminary studies show that this assay work well for the isolation of exhaled extracellular vesicles (exh-EVs) from exhaled breath condensates (EBC) to capture and characterize miRNAs contained in exh-EVs. Because assembling a large enough cohort of asymptomatic subjects requires time, a complementary approach of using humanized animal models has been chosen to comprehensively assess the robustness and sensitivity of transcriptomic (miRNA and mRNA) and proteomic biomarkers contained in tumor exh-EVs and to enable sensitive detection of human primary and secondary lung cancers during their early development. The results of preliminary analyses demonstrate that the purification of exh-EVs with EV-CATCHER® offers specificity and sensitivity, which will be critical for the targeted purification of tumor exh-EVs from the EBC of transgenic, orthotopic, and Patient-Derived Xenograft (PDX) animal models of human lung cancers.

The invention relates to the technical field of biological medicines, and mainly relates to application of tenascin-C (Tenascinin-C, TNC) as a prevention and / or treatment target in silicosis pulmonary fibrosis. The technical problem to be solved by the invention is to provide a new target selection for prevention and / or treatment of silicosis and pulmonary fibrosis. According to the technical scheme for solving the technical problem, the invention provides the application of the TNC as a target spot for preventing and / or treating silicosis pulmonary fibrosis. It is found that TNC is highly expressed in silicosis pulmonary fibrosis lung tissue, and expression of extracellular matrix genes and protein of human lung fibroblasts can be increased; the invention further finds that the expression of Collagen I and Fibronectin in the fibroblast can be obviously reduced by knocking down the Tnc in the lung tissue fibroblast, so that the progress of pulmonary fibrosis is inhibited. The invention provides a new target selection for prevention and / or treatment of silicosis pulmonary fibrosis, and has a good application prospect.

The present application relates to a kind of sine formula breathing device for aircraft oxygen mask test, belong to breathing device technical field.The device includes the driving unit for the power of piston cylinder piston movement, piston cylinder simulating human lung, gas pipeline connecting piston cylinder and first three-way valve, suction pipeline and exhalation pipeline installed between first three-way valve and second three-way valve, mass flow meter arranged on suction pipeline, heating and humidifying unit arranged on exhalation pipeline, pressure temperature table for monitoring ambient pressure and temperature, control unit electrically connected with pressure temperature table, mass flow meter, first three-way valve, second three-way valve and servo cylinder respectively.The device can control the tidal volume of simulated human sine formula breathing, respiratory volume, exhalation temperature and exhalation humidity, also can correct the motion state of driving unit to change tidal volume and respiratory volume, simple operation, high precision, applicable to different pressure environment.

This invention relates to a method for extracting compound Alisma alkaloid A from Alisma plantago-aquatica and its application, effectively solving the problem of extracting Alisma alkaloids from Alisma plantago-aquatica and enabling its application in the preparation of drugs for treating lung cancer. This compound, Alisma alkaloid A, significantly reduces cell viability and Bcl2 expression, induces apoptosis and mitochondrial membrane depolarization in A549 lung cancer cells, and significantly increases the expression of Bax, Caspase3, and Caspase9, without affecting normal human lung epithelial cells BEAS-2B. It has the effect of inducing apoptosis in A549 cells through the mitochondrial apoptosis pathway, thus realizing the application of Alisma alkaloid A in the preparation of drugs for treating lung cancer. The method of this invention is scientifically sound, novel, unique, and easy to operate, effectively extracting compound Alisma alkaloid A from Alisma plantago-aquatica. This compound has the effect of inducing apoptosis in A549 cells through the mitochondrial apoptosis pathway, realizing the application of Alisma alkaloid A in the preparation of drugs for treating lung cancer, and expanding the medicinal and commercial value of Alisma plantago-aquatica.